GeneBioTech Co. Ltd Asset Resilience Ratio
GeneBioTech Co. Ltd asset resilience ratio. GeneBioTech Co. Ltd (086060) has an Asset Resilience Ratio of 22.68% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GeneBioTech Co. Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GeneBioTech Co. Ltd (2009–2025)
Asset resilience ratio of GeneBioTech Co. Ltd from 2009 to 2025. This chart shows how GeneBioTech Co. Ltd's Asset Resilience Ratio has changed over time. Read GeneBioTech Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GeneBioTech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GeneBioTech Co. Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩18.21 Billion | 22.68% |
| Total Liquid Assets | ₩18.21 Billion | 22.68% |
Asset Resilience Insights
- Good Liquidity Position: GeneBioTech Co. Ltd maintains a healthy 22.68% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GeneBioTech Co. Ltd Industry Peers by Asset Resilience Ratio
Compare GeneBioTech Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
GeneBioTech Co. Ltd Asset Resilience Ratio by Year (2009–2025)
GeneBioTech Co. Ltd asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for GeneBioTech Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.24% | ₩15.31 Billion ≈ $10.38 Million |
₩75.63 Billion ≈ $51.26 Million |
-9.49pp |
| 2024-12-31 | 29.73% | ₩21.40 Billion ≈ $14.51 Million |
₩71.99 Billion ≈ $48.79 Million |
-3.62pp |
| 2023-12-31 | 33.35% | ₩22.02 Billion ≈ $14.92 Million |
₩66.02 Billion ≈ $44.74 Million |
+13.38pp |
| 2022-12-31 | 19.97% | ₩12.79 Billion ≈ $8.67 Million |
₩64.04 Billion ≈ $43.40 Million |
-3.70pp |
| 2021-12-31 | 23.67% | ₩14.29 Billion ≈ $9.68 Million |
₩60.37 Billion ≈ $40.91 Million |
-15.21pp |
| 2020-12-31 | 38.88% | ₩24.14 Billion ≈ $16.36 Million |
₩62.09 Billion ≈ $42.07 Million |
+2.02pp |
| 2019-12-31 | 36.86% | ₩25.04 Billion ≈ $16.97 Million |
₩67.93 Billion ≈ $46.04 Million |
-5.28pp |
| 2018-12-31 | 42.14% | ₩30.60 Billion ≈ $20.74 Million |
₩72.63 Billion ≈ $49.22 Million |
+17.88pp |
| 2017-12-31 | 24.25% | ₩14.44 Billion ≈ $9.79 Million |
₩59.54 Billion ≈ $40.35 Million |
+1.78pp |
| 2016-12-31 | 22.48% | ₩13.30 Billion ≈ $9.01 Million |
₩59.16 Billion ≈ $40.09 Million |
+10.94pp |
| 2015-12-31 | 11.54% | ₩5.68 Billion ≈ $3.85 Million |
₩49.21 Billion ≈ $33.35 Million |
-0.52pp |
| 2014-12-31 | 12.06% | ₩5.71 Billion ≈ $3.87 Million |
₩47.34 Billion ≈ $32.08 Million |
+0.61pp |
| 2013-12-31 | 11.45% | ₩5.54 Billion ≈ $3.75 Million |
₩48.35 Billion ≈ $32.77 Million |
+2.73pp |
| 2012-12-31 | 8.71% | ₩3.99 Billion ≈ $2.70 Million |
₩45.78 Billion ≈ $31.02 Million |
-0.74pp |
| 2011-12-31 | 9.45% | ₩4.37 Billion ≈ $2.96 Million |
₩46.27 Billion ≈ $31.36 Million |
-5.75pp |
| 2010-12-31 | 15.20% | ₩4.49 Billion ≈ $3.05 Million |
₩29.56 Billion ≈ $20.03 Million |
-6.53pp |
| 2009-12-31 | 21.73% | ₩6.38 Billion ≈ $4.32 Million |
₩29.36 Billion ≈ $19.90 Million |
-- |
About GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.